30-day average of 12 articles · scale −100 to +100
Across 12 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Gilead Sciences news is Somewhat Bullish (+50)
on a scale from −100 to +100.
That is up 9 points from the previous 30 days (+41).
📈 Gilead Q3 EPS beat estimates by 15.6%, extending six quarters of outperformance.
💰 Revenue rose 6.8% YoY to $8.3B driven by strong HIV franchise performance.
Bullish +65
Gilead Sciences (GILD) Q3 2026 Earnings
AI-generated analysis
Key insights
📈 Gilead reported Q3 2026 non-GAAP EPS of $2.55, beating the $2.21 consensus estimate by 15.6% and extending a six-quarter run of exceeding analyst expectations.
💰 Revenue reached $8.3 billion, topping the $7.8 billion estimate by 6.32% and rising 6.8% year over year driven by strong HIV franchise performance.
🔬 HIV sales surged 18% to drive overall growth, with Biktarvy up 10% and prevention revenues nearly doubling due to the rapid commercial ramp of Yeztugo.
📊 Product sales excluding Veklury increased 16% to $8.20 billion, fueled by higher average realized prices and favorable inventory dynamics across key assets.
🚀 Gilead raised full-year 2026 product sales guidance to $31.0–$31.3 billion, a cumulative increase of $1.60 billion since the start of the year.
⚖️ Product gross margin expanded to 81.0% non-GAAP following the expiration of a royalty-related obligation, improving profitability on core products.
📉 GAAP diluted EPS declined to $1.94 from the prior year due to net losses from equity securities and higher tax rates, masking underlying operational strength.
💸 Significant acquired IPR&D charges of $12.4 billion are included in guidance, resulting in a projected GAAP diluted loss of $(4.40)–$(4.05) per share for the full year.
📉 Veklury revenues dropped 69% to approximately $300 million as expected due to lower COVID-19 hospitalizations, though guidance remains unchanged at this level.
⚠️ The Biktarvy Medicare Maximum Fair Price is scheduled to affect revenue starting January 1, 2028, potentially impacting future HIV franchise growth.
📈 Bullish signals
📈Gilead delivered a standout Q3 with non-GAAP EPS of $2.55, beating estimates by 15.6% and extending a six-quarter streak of exceeding analyst expectations.
💰Revenue of $8.3 billion surpassed the $7.8 billion consensus, rising 6.8% year over year driven by an 18% surge in HIV sales.
🔬The twice-yearly lenacapavir PrEP product Yeztugo rapidly ramped to generate $305 million, a near-doubling of prevention revenues compared to the prior year.
📊Product sales excluding Veklury grew 16% to $8.20 billion, fueled by higher average realized prices and strong demand for Biktarvy and Descovy.
🚀Gilead raised full-year 2026 product sales guidance to $31.0–$31.3 billion, reflecting confidence in its core business momentum.
⚖️Product gross margin expanded to 81.0% non-GAAP following the expiration of a royalty-related obligation, enhancing profitability on existing assets.
📉 Risk factors
📉GAAP diluted EPS fell to $1.94 from the prior year due to net losses from equity securities and higher operating expenses.
💸Significant acquired IPR&D charges of $12.4 billion weigh heavily on per-share metrics, resulting in a projected full-year GAAP loss of $(4.40)–$(4.05).
📉Cell therapy revenues declined 18% year over year due to competitive headwinds in the sector.
📉Veklury revenues dropped 69% to approximately $300 million as lower COVID-19 hospitalizations reduced demand for the antiviral treatment.
Article
Gilead Sciences reported third-quarter fiscal 2026 earnings on October 29, 2026, significantly beating analyst expectations with non-GAAP EPS of $2.55 versus a consensus of $2.21 and revenue of $8.3 billion against an estimate of $7.8 billion. This performance extended the company's streak of exceeding EPS estimates to six consecutive quarters, driven primarily by robust growth in its HIV franchise where product sales excluding Veklury surged 16% year-over-year.
The standout quarter was fueled by an 18% increase in HIV sales led by the blockbuster drug Biktarvy and a near-doubling of prevention revenues. The twice-yearly lenacapavir PrEP product, Yeztugo, rapidly ramped up to generate $305 million compared to just $39 million a year earlier. Other segments showed mixed results, with liver disease sales rising 13% due to Livdelzi demand and pricing, while cell therapy revenues declined 18% amid competitive headwinds.
Despite the strong operational performance, GAAP diluted EPS fell to $1.94 from the prior year due to net losses on equity securities and higher operating expenses. Gilead raised its full-year 2026 product sales guidance to a range of $31.0 billion to $31.3 billion, reflecting confidence in its core business despite significant acquired IPR&D charges totaling $12.4 billion that weigh heavily on per-share metrics.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Gilead Sciences stock closed at USD 150.11 on September 18, 2026, trading near the top of its 52-week range and reflecting a robust year-to-date gain of 22.3 percent from the start of 2026. The company's market capitalization reached approximately USD 186.12 billion as of September 20, 2026, with analysts maintaining a Moderate Buy consensus view supported by an average price target around USD 158.
Analysts highlight the company's long-acting HIV prevention and treatment portfolio, specifically including twice-yearly injectable lenacapavir and flagship oral therapy Biktarvy, as central to its growth narrative. While overall growth is characterized as cautious due to competitive pressures and pricing constraints, the intrinsic fair value estimate for Gilead Sciences recently rose by 1.43 percent, though shares currently trade roughly 17.7 percent above this estimate.
Strategically, Gilead Sciences secured a new agreement with the Pan American Health Organization to facilitate access to lenacapavir across Latin America and the Caribbean, expanding its HIV prevention footprint in the region. The company also maintains a dividend schedule with a payment date set for September 29, 2026, offering income components to investors while awaiting upcoming earnings results expected in late October.
Investors are closely monitoring Gilead Sciences' performance in HIV, oncology, and antiviral franchises relative to analyst expectations. The stock embodies a balance between the upside potential linked to its innovative long-acting prevention drugs and the valuation premium already priced into the shares by the market.
📈 GILD stock closed at USD 150.11 with a 22.3% year-to-date gain.
🔬 Analysts maintain Moderate Buy consensus with average price target of USD 158.
💊 Growth relies on lenacapavir and Biktarvy HIV prevention drugs.
🌍 New agreement expands lenacapavir access across Latin America and Caribbean.
📈 Gilead Sciences stock closed at USD 150.11 on September 18, 2026, near the top of its 52-week trading range after a 22.3 percent year-to-date gain.
💰 The company's market capitalization reached USD 186.12 billion as of September 20, 2026, reflecting strong investor confidence in its biopharma portfolio.
🔬 Analysts maintain a Moderate Buy consensus with an average price target around USD 158, indicating potential upside relative to the recent closing level.
💊 Gilead's growth narrative relies heavily on its long-acting HIV prevention drugs, including twice-yearly injectable lenacapavir and oral therapy Biktarvy.
🌍 A new agreement with the Pan American Health Organization aims to expand access to lenacapavir for HIV prevention across Latin America and the Caribbean.
💵 The company offers a dividend payable on September 29, 2026, adding an income component to its total return profile for shareholders.
📅 Investors await upcoming earnings results expected in late October to scrutinize revenue and cash flow trends across HIV, oncology, and antiviral franchises.
Bullish Signals
Stock closed at USD 150.11, up 22.3% year-to-date.
Analysts see upside with average target of USD 158.
HIV portfolio including lenacapavir drives future growth.
Secured agreement to expand lenacapavir access in Latin America.
Risk Factors
Growth cautious due to HIV market competition and pricing limits.
Gilead Sciences stock closed at USD 150.11 near the top of its 52-week range, reflecting a robust 22.3 percent year-to-date gain from the start of 2026.
Analysts maintain a Moderate Buy consensus with an average price target around USD 158, suggesting potential upside relative to the current trading level.
The company's long-acting HIV prevention portfolio, including lenacapavir and Biktarvy, is expected to remain central to its growth narrative over the coming years.
Gilead Sciences secured a strategic agreement with the Pan American Health Organization to facilitate access to lenacapavir across Latin America and the Caribbean.
Risk Factors
Analysts characterize overall growth as cautious due to existing competitive pressures and pricing constraints within the HIV treatment market.
The stock trades approximately 17.7 percent above its estimated intrinsic fair value, implying a valuation premium that may limit immediate upside potential.
Gilead Sciences stock rose approximately 1.45% to $148.42 on September 16, 2026, trading near the upper end of its 52-week range following an announcement to expand royalty-free licensing for its investigational HIV prevention drug, lenacapavir. The company broadened access to this once-yearly treatment across 120 countries with high infection rates, primarily targeting low- and lower-middle-income regions as part of its global access strategy.
The expansion aligns with the drug's progression through Phase 3 trials, with potential market introduction expected around 2028. The deal involves partnerships including the Pan American Health Organization to facilitate access in Latin America and the Caribbean, signaling Gilead's commitment to broadening reach despite ongoing pricing and margin considerations associated with regional purchasing systems.
Fundamentally, Gilead reported earnings beats for the first and second quarters of 2026, though it maintains a negative net income margin of approximately -10.64% over that period. With trailing twelve-month earnings per share at -$2.66, investors are focusing on revenue growth and pipeline milestones rather than traditional P/E valuations, which currently stand at 6.05x sales, significantly above historical and industry medians.
📈 Stock gained 1.45% to $148.42 following expanded HIV prevention licensing news.
🌍 Royalty-free voluntary agreements now cover 120 countries with high HIV infection rates.
💰 Reported strong Q1/Q2 earnings beats despite -10.64% negative net income margin.
📉 Trades at 6.05x price-to-sales, significantly above historical and industry medians.
⚠️ High valuation risks clinical setbacks that could prompt a valuation reset.
📈 Gilead Sciences stock gained 1.45% to $148.42 on September 16, 2026, trading near its 52-week high of $157.29 following news of expanded HIV prevention licensing.
🌍 The company expanded royalty-free voluntary licensing agreements for its once-yearly lenacapavir drug to include access across 120 countries with high HIV infection rates.
💰 Gilead reported strong earnings beats in Q1 and Q2 2026, though it maintains a negative net income margin of approximately -10.64% over the same period.
📉 The stock trades at a price-to-sales ratio of 6.05x, which is significantly above its historical median of 3.7x and the broader industry median.
💸 Gilead announced a cash dividend of $0.82 per share with an ex-dividend date of September 15, 2026, continuing capital returns to shareholders.
🎯 Analyst consensus recommends a Hold stance on Gilead Sciences with a target price of $158.15, representing a potential upside of 7.86% from recent levels.
⚠️ The current valuation embeds substantial expectations for the HIV prevention franchise, creating risk that clinical setbacks or delays could prompt a valuation reset.
🏥 Gilead markets its twice-yearly formulation as Yeztugo in the United States while advancing once-yearly lenacapavir globally for potential 2028 market introduction.
Bullish Signals
Stock gained 1.45% to $148.42 near 52-week high.
Broadened lenacapavir access across 120 countries.
Reported strong earnings beats in Q1 and Q2 2026.
Announced $0.82 cash dividend with ex-date Sept 15.
Risk Factors
P/S ratio 6.05x vs historical median 3.7x.
EPS -$2.66; traditional P/E valuation less meaningful.
GuruFocus estimates 38.6% overvalued vs intrinsic $106.55.
Analyst consensus Hold with target price $158.15.
Bullish Signals
Gilead Sciences stock gained 1.45% to $148.42 on September 16, 2026, trading near the upper end of its 52-week range following an expansion of royalty-free licensing for its HIV prevention drug lenacapavir.
The company broadened access to its investigational once-yearly lenacapavir across 120 countries with high HIV infection rates, primarily targeting low- and lower-middle-income regions.
Gilead Sciences reported strong earnings beats in both the first and second quarters of 2026, with results ahead of market expectations despite an overall negative net income margin.
The company announced a cash dividend of $0.82 per share with an ex-dividend date of September 15, 2026, demonstrating continued practice of returning capital to shareholders.
Risk Factors
Gilead Sciences trades at a price-to-sales ratio of 6.05x, which is significantly above its historical median of about 3.7x and the broader industry median.
The stock's trailing twelve-month earnings per share are -$2.66, reflecting negative profitability that makes traditional P/E valuation less meaningful and shifts focus to revenue growth.
GuruFocus estimates the stock is approximately 38.6% overvalued relative to its intrinsic value of $106.55, raising risks that clinical setbacks or delays could prompt a valuation reset.
Analyst consensus recommends a Hold stance with a target price of $158.15, suggesting the market views the licensing expansion as positive but not yet decisive enough to shift the overall risk-reward assessment.
Gilead Sciences has agreed to acquire Arcellx in an all-cash deal valued at approximately $7.8 billion, marking a significant strategic expansion into the cell therapy space. The transaction is structured as a tender offer followed by a merger, with Gilead already holding an 11.5% stake in Arcellx prior to the closing of the deal.
Gilead will pay $115 per share in cash at closing, plus a contingent value right (CVR) worth up to $5 per share if specific sales milestones are met. The CVR is tied to anito-cel reaching cumulative global net sales of at least $6 billion by the end of 2029, representing a total premium of roughly 87% over Arcellx's previous closing price.
The acquisition targets anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma. Gilead expects the deal to be accretive to earnings per share starting in 2028, assuming FDA approval is granted by the anticipated decision date of December 23, 2026.
This move consolidates control over a program Gilead has collaborated on since 2022, positioning it against established competitors like Johnson & Johnson and Legend Biotech. The acquisition aims to capture a large commercial opportunity in the multiple myeloma CAR-T category while leveraging Gilead's existing manufacturing and distribution capabilities.
📈 Gilead agrees to acquire Arcellx for $7.8 billion in all-cash deal.
💰 Deal includes CVR contingent on anito-cel reaching $6B sales by 2029.
⏳ FDA decision expected by December 23, 2026, keeping asset near launch.
📊 Acquisition expected to be accretive to Gilead EPS starting in 2028.
📉 Gilead stock dipped ~1% premarket following large cash commitment announcement.
📈 Gilead Sciences agreed to acquire Arcellx for $7.8 billion in an all-cash deal, valuing the company at $115 per share plus a potential $5 contingent value right.
💰 The acquisition includes a CVR that pays out if anito-cel achieves $6 billion in cumulative global net sales by the end of 2029.
🏥 Gilead is acquiring anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma.
⏳ The FDA is expected to make a decision on anito-cel by December 23, 2026, keeping the asset in a near-launch window.
📊 Gilead expects the acquisition to be accretive to earnings per share starting in 2028, assuming regulatory approval is obtained.
🤝 The deal consolidates control of a program Gilead has been collaborating on with Arcellx since 2022.
📉 Gilead's stock dipped about 1% in premarket trade following the announcement of the large cash commitment.
🔬 Anito-cel faces competition from established players like Johnson & Johnson and Legend Biotech's Carvykti in the multiple myeloma CAR-T market.
📈 Arcellx stock surged roughly 80% in premarket trading as it repriced toward the definitive buyout price of $115 per share.
🏢 Gilead already owns approximately 11.5% of Arcellx's outstanding shares before the transaction closes.
Bullish Signals
Acquired Arcellx for $7.8B to expand cell therapy market.
Targets $6B sales milestone in multiple myeloma CAR-T.
Deal accretive to EPS starting 2028 assuming FDA approval.
Consolidates collaboration since 2022, reducing integration risk.
FDA decision on anito-cel expected by Dec 23, 2026.
Risk Factors
Stock dipped 1% after $7.8B Arcellx acquisition announcement.
Acquired asset faces intense competition in CAR-T category.
Bullish Signals
Gilead Sciences agreed to acquire Arcellx for $7.8 billion in an all-cash deal, significantly expanding its presence in the high-growth cell therapy market.
The acquisition of anitocabtagene autoleucel (anito-cel) targets a large commercial opportunity in the multiple myeloma CAR-T category with a potential $6 billion sales milestone.
Gilead expects the deal to be accretive to earnings per share starting in 2028, assuming FDA approval is granted for the lead therapy.
The transaction consolidates control of a program Gilead has collaborated on since 2022, leveraging existing knowledge and reducing integration risk.
The FDA decision on anito-cel is expected by December 23, 2026, providing a clear near-term timeline for potential revenue generation.
Risk Factors
Gilead's stock dipped about 1% in premarket trade following the announcement of the $7.8 billion cash commitment to acquire Arcellx.
The acquired asset faces intense competition from established players like Johnson & Johnson and Legend Biotech in the multiple myeloma CAR-T category.
Gilead Sciences (NASDAQ:GILD) is highlighted as a quality dividend stock within the ChartMill screening methodology, which prioritizes dividend sustainability over yield alone. The company meets specific criteria including a Dividend Rating of 7, a Profitability Rating of 7, and a Health Rating of 6, indicating a robust financial profile suitable for income investors seeking stability above market averages.
The analysis details Gilead's strong operational metrics, noting a 3.98% dividend yield supported by a Return on Invested Capital of 22.55%, an operating margin of 38.62%, and consistent positive operating cash flow over the past five years. These figures suggest the dividend is funded by a business generating significant cash rather than relying on distressed financial conditions or falling share prices.
Despite these strengths, the article identifies key risks centered on recent earnings performance. Gilead reported negative net income in the past year, resulting in a negative trailing payout ratio which flags potential dividend sustainability concerns if the situation persists. However, forward estimates project an annual EPS growth of roughly 10%, suggesting a potential earnings rebound that could support the current dividend level.
Beyond yield-focused screens, Gilead also qualifies for quality and value-oriented lists due to its high margins, strong cash conversion, controlled debt levels relative to free cash flow, and established market position. The company is characterized as a large, financially strong entity with manageable debt obligations, though investors are advised to monitor the debt-to-equity ratio which may be elevated due to share buybacks.
📊 Gild holds high Dividend (7) and Profitability (7) ratings for sustainable income.
💰 Offers 3.98% yield, well above S&P 500 average with long payment history.
📈 Strong efficiency shown by 22.55% ROIC and 38.62% operating margins.
⚠️ Recent negative net income creates payout pressure despite forward 10% EPS growth.
📊 Gilead Sciences holds a ChartMill Dividend Rating of 7 and a Profitability Rating of 7, meeting strict criteria for sustainable income investing.
💰 The company offers a 3.98% dividend yield, significantly higher than the S&P 500 average while maintaining a long payment track record.
📈 Operational efficiency is strong with a Return on Invested Capital of 22.55%, an operating margin of 38.62%, and gross margins at 79.60%.
💧 Cash flow health is robust, evidenced by positive operating cash flow reported in each of the past five years.
🛡️ Financial stability is supported by a low bankruptcy risk indicated by an Altman-Z score of 4.54 and manageable debt levels.
⚠️ A primary risk factor is recent negative net income which created a negative trailing payout ratio, flagging potential dividend pressure.
🔮 Forward estimates project an annual EPS growth of roughly 10%, suggesting a potential earnings rebound to support the dividend.
📉 The debt-to-equity ratio is elevated due to share buybacks but remains manageable relative to free cash flow with a ratio of 2.03.
🏆 Gilead qualifies for multiple quality screens including 'Quality At A Fair Price' and 'Blue Chip' due to strong margins and established status.
Bullish Signals
Gilead Sciences maintains a high Dividend Rating of 7 and Profitability Rating of 7, indicating a sustainable dividend strategy backed by strong fundamentals.
The company generates positive operating cash flow for five consecutive years, providing a reliable funding source for its shareholder returns.
Gilead demonstrates exceptional operational efficiency with a Return on Invested Capital of 22.55% and an operating margin of 38.62%.
The stock is recognized by multiple ChartMill screens, including 'Quality At A Fair Price' and 'Blue Chip', for its strong balance sheet and cash conversion capabilities.
Debt levels are manageable with a debt-to-free-cash-flow ratio of 2.03, suggesting the company could pay down debt in roughly two years using current cash flow.
Risk Factors
Gilead reported negative net income in the past year, resulting in a negative trailing payout ratio that flags potential dividend sustainability risks.
The fundamental analysis sustainability subscore indicates the dividend level could be at risk if the recent earnings decline persists.
Gilead Sciences (GILD) is recommended as a buy despite a temporary $11.5 billion impairment and research and development charge that distorts current financial optics but does not reflect underlying fundamentals. The article argues that this specific accounting event creates a buying opportunity before the upcoming Q2 earnings report clarifies the company's true performance.
The company's HIV franchise remains robust, growing at an 8% rate with patent protection extending through 2036 and plans for up to seven new product launches by 2033. Simultaneously, Gilead is undergoing an oncology inflection point driven by the first-line expansion of its Trodelvy drug and strategic acquisitions aimed at building a next-generation pipeline.
Valuation metrics suggest Gilead is undervalued relative to peers, trading at approximately 14.5x normalized forward earnings. This represents a 20% to 25% discount compared to competitors, even though the company maintains superior margins and clear growth visibility, making it an attractive investment target.
📈 Buy rating ignores $11.5B IPR&D charge distorting current optics.
🔒 HIV franchise grows 8% with patents secured through 2036.
💊 Oncology accelerates via Trodelvy expansion and strategic acquisitions.
💰 Trades at 14.5x earnings, a 20–25% discount to peers.
📅 Q2 earnings will clarify true performance after accounting charge.
📈 Gilead Sciences is rated as a buy due to a temporary $11.5 billion IPR&D charge that distorts current financial optics without harming fundamentals.
🔒 The HIV franchise is growing at 8% with patent protection secured through 2036 and up to seven new launches scheduled by 2033.
💊 Oncology growth is accelerating led by Trodelvy's first-line expansion and strategic acquisitions building a next-gen pipeline.
💰 Gilead trades at 14.5x normalized forward earnings, offering a 20–25% discount to peers despite superior margins.
📅 The article anticipates Q2 earnings will clarify the company's true performance after the accounting charge is accounted for.
Bullish Signals
Trades at 20–25% discount with superior profit margins.
HIV franchise shows 8% growth through 2036 patent runway.
Oncology inflection point driven by Trodelvy expansion.
Seven new launches planned by 2033 for revenue visibility.
Bullish Signals
Gilead trades at a significant 20–25% discount to peer companies while maintaining superior profit margins and clear growth visibility.
The HIV franchise demonstrates strong momentum with 8% growth and a long-term patent runway extending through 2036.
Strategic acquisitions and the first-line expansion of Trodelvy indicate a successful oncology inflection point and pipeline development.
Up to seven new product launches are planned by 2033, providing sustained revenue visibility for the business.
Gilead Sciences, Inc. (NASDAQ: GILD) saw activity from several institutional investors in the first quarter of 2026. Dorsey Wright & Associates acquired a new position valued at approximately $1.32 million for 9,474 shares. Other funds including Brighton Jones LLC, Bison Wealth LLC, Sivia Capital Partners LLC, Ieq Capital LLC, and Diversify Advisory Services LLC also increased their stakes or established new positions during the second and fourth quarters.
Analyst sentiment remains mixed with a consensus 'Moderate Buy' rating and an average target price of $159.04. Truist Financial and Maxim Group recently upgraded or maintained buy ratings, while Daiwa Securities Group and Royal Bank Of Canada lowered their price targets to $150.00 and $120.00 respectively. Weiss Ratings slightly downgraded the stock from a 'buy (b)' to a 'buy (b-)' rating.
Insider trading activity shows CEO Daniel Patrick O'day sold 15,000 shares in July for approximately $1.89 million under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 2.41%. CFO Johanna Mercier also sold 3,000 shares in June. Over the last ninety days, insiders collectively sold 77,000 shares worth nearly $10 million, though they still hold a significant portion of the company's stock.
Financially, Gilead reported strong quarterly results with revenue of $6.96 billion, beating estimates by $50 million, and EPS of $2.03 versus a consensus of $1.91. The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.89 and recently paid a quarterly dividend of $0.82 per share, yielding 2.4%.
📈 Dorsey Wright acquired $1.32M stake in Q1.
📊 Institutional ownership is 83.67% with hedge fund growth.
💰 Revenue hit $6.96B, beating estimates by $50M.
💵 Quarterly dividend of $0.82 yields 2.4% annually.
📉 CEO sold 15,000 shares for $1.89M in July.
📈 Dorsey Wright & Associates acquired a new position in Gilead Sciences valued at approximately $1.32 million during the first quarter.
📊 Institutional ownership stands at 83.67%, with multiple hedge funds like Ieq Capital LLC and Sivia Capital Partners increasing their stakes significantly.
📉 CEO Daniel Patrick O'day sold 15,000 shares for $1.89 million in July under a pre-arranged trading plan, representing a 2.41% decrease in his holdings.
💰 Gilead reported quarterly revenue of $6.96 billion and EPS of $2.03, beating analyst estimates by $50 million and $0.12 respectively.
📈 Analyst consensus is 'Moderate Buy' with an average target price of $159.04, though some firms like Daiwa Securities lowered targets to $150.
💵 The company recently paid a quarterly dividend of $0.82 per share, resulting in an annualized yield of 2.4% for shareholders.
📉 Financial metrics show a price-to-earnings ratio of 18.29 and a debt-to-equity ratio of 0.89, indicating a stable financial position.
🌍 Gilead focuses on antiviral therapies for HIV and hepatitis, with expansion into oncology, cell therapy, and inflammatory diseases.
Bullish Signals
Revenue beat estimates by $50M to reach $6.96 billion.
EPS of $2.03 exceeded consensus of $1.91.
Institutional investors increased or established new positions.
Analysts rate stock Moderate Buy with $159.04 target.
Debt-to-equity ratio is 0.89 and current ratio is 1.97.
Risk Factors
CEO sold 15,000 shares worth $1.89 million.
Daiwa lowered price target to $150.
Royal Bank of Canada cut target to $120.
Weiss downgraded rating from buy (b) to buy (b-).
Bullish Signals
Gilead Sciences beat quarterly revenue estimates by $50 million to reach $6.96 billion, demonstrating strong commercial performance.
The company exceeded earnings per share expectations with a reported EPS of $2.03 compared to the consensus of $1.91.
Multiple institutional investors including Dorsey Wright & Associates and Ieq Capital LLC have increased or established new positions in the stock.
Analysts maintain a 'Moderate Buy' consensus rating with an average target price of $159.04, suggesting continued confidence in the business.
Gilead maintains a robust balance sheet with a debt-to-equity ratio of 0.89 and a current ratio of 1.97.
Risk Factors
CEO Daniel Patrick O'day sold 15,000 shares worth $1.89 million in July, signaling a reduction in personal equity exposure.
Daiwa Securities Group lowered its price target from $161.00 to $150.00, indicating some analysts see limited upside potential.
Royal Bank Of Canada reduced its price target to $120.00 and assigned a 'sector perform' rating, reflecting cautious sentiment.
Weiss Ratings downgraded the stock from a 'buy (b)' to a 'buy (b-)', suggesting a slight reduction in investment quality perception.
Bleakley Financial Group LLC significantly increased its stake in Gilead Sciences, Inc. (GILD) by 80.3% during the first quarter, purchasing an additional 24,649 shares to hold a total of 55,332 shares valued at $7.71 million. Other institutional investors also adjusted their positions, with Principal Financial Group Inc. boosting its stake by 0.4% and Chicago Partners Investment Group LLC increasing holdings by 8.3%. New entrants including Bedel Financial Consulting Inc., IFC Advisors LLC, and HBW Advisory Services LLC added to their Gilead positions, while institutional ownership remains high at 83.67%.
Gilead Sciences reported a quarterly dividend of $0.82 per share paid on June 29th, representing an annualized yield of 2.5% with a payout ratio of 44.69%. The stock currently trades with a market capitalization of $161.45 billion and a price-to-earnings ratio of 17.72. Analyst sentiment is mixed but generally positive, with a consensus target price of $159.04 from twenty-six equities research analysts, though recent reports show some firms lowering their price targets while others maintain buy ratings.
Insider trading activity shows net selling over the last ninety days, totaling 77,000 shares valued at approximately $9.98 million. CEO Johanna Mercier sold 28,000 shares under a pre-arranged Rule 10b5-1 plan, and CFO Andrew D. Dickinson sold 3,000 shares. Despite these sales, insiders still hold significant equity, with the CEO owning roughly $16.5 million and the CFO holding approximately $21.5 million in company stock.
📈 Bleakley Financial raised Gilead holdings by 80.3% to 55,332 shares.
💰 Gilead paid a $0.82 quarterly dividend with a 2.5% annualized yield.
📊 Stock trades at $161.45 billion market cap and 17.72 P/E ratio.
📉 Insiders sold 77,000 shares totaling $9.98 million in ninety days.
🎯 Wall Street Zen upgraded Gilead from 'hold' to 'buy' rating.
📈 Bleakley Financial Group LLC raised its Gilead holdings by 80.3% to 55,332 shares worth $7.71 million during the first quarter.
🏦 Principal Financial Group Inc. increased its stake by 0.4%, now owning 1,769,886 shares valued at $246.67 million.
💰 Gilead Sciences paid a quarterly dividend of $0.82 per share on June 29th with an annualized yield of 2.5%.
📊 The stock has a market cap of $161.45 billion and trades at a P/E ratio of 17.72.
📉 Insider Johanna Mercier sold 28,000 shares for $3.68 million under a pre-arranged trading plan.
📉 CFO Andrew D. Dickinson sold 3,000 shares for $376,200 following the quarterly dividend payment.
📉 Total insider sales over the last ninety days reached 77,000 shares valued at $9.98 million.
🎯 Wall Street Zen upgraded Gilead from a 'hold' to a 'buy' rating in a recent research report.
📉 Cantor Fitzgerald maintained an 'overweight' rating with a price objective of $155.00.
📉 Morgan Stanley lowered its target price to $166.00 but retained an 'overweight' rating.
📉 Leerink Partners reduced its target price from $148.00 to $146.00 in a report dated May 8th.
📉 Truist Financial cut its price target to $156.00 while maintaining a 'buy' rating.
🏥 Gilead focuses on antiviral therapies for HIV and hepatitis, plus oncology and cell therapy.
📈 Institutional investors own 83.67% of the company's outstanding stock.
Bullish Signals
Major institutional position increased by 80.3%.
Principal Financial added 7,880 shares to $246M portfolio.
Chicago Partners raised holdings by 8.3%.
New entrants initiated or increased positions.
Wall Street Zen upgraded stock to 'buy'.
Cantor Fitzgerald targets $155.00 price objective.
Morgan Stanley maintains 'overweight' rating.
Truist Financial assigned 'buy' rating.
Dividend yield is 2.5% with 44.69% payout ratio.
Institutional ownership stands at 83.67%.
Risk Factors
CEO sold 28,000 shares worth $3.68 million.
CFO sold 3,000 shares worth $376,200.
Total insider selling reached $9.98 million in 90 days.
Leerink Partners lowered price target to $146.
Morgan Stanley reduced price target to $166.
Bullish Signals
Bleakley Financial Group LLC significantly increased its position by 80.3%, signaling strong institutional confidence in the biopharmaceutical sector.
Principal Financial Group Inc. boosted its stake, adding 7,880 shares to a massive existing portfolio valued at over $246 million.
Chicago Partners Investment Group LLC raised its holdings by 8.3%, acquiring an additional 590 shares worth over $1 million.
New institutional entrants Bedel Financial Consulting Inc., IFC Advisors LLC, and HBW Advisory Services LLC initiated or increased positions in Gilead.
Wall Street Zen upgraded the stock from a 'hold' to a 'buy' rating, indicating improved analyst sentiment.
Cantor Fitzgerald reiterated an 'overweight' rating with a specific price objective of $155.00.
Morgan Stanley maintains an 'overweight' rating despite lowering its target price, suggesting continued long-term confidence.
Truist Financial assigned a 'buy' rating to the stock even after reducing its price target slightly.
The company offers a consistent dividend yield of 2.5% with a manageable payout ratio of 44.69%.
Institutional ownership remains robust at 83.67%, indicating broad market acceptance and stability.
Risk Factors
CEO Johanna Mercier sold 28,000 shares worth $3.68 million, representing an 18.21% decrease in her personal ownership.
CFO Andrew D. Dickinson sold 3,000 shares worth $376,200, reducing his stake by 1.72%.
Total insider selling over the last ninety days reached $9.98 million, which may indicate profit-taking or portfolio rebalancing.
Leerink Partners lowered its price target from $148.00 to $146.00, reflecting a slight bearish adjustment.
Morgan Stanley reduced its price target from $168.00 to $166.00, indicating some analysts see limited upside near current levels.
Truist Financial cut its price target from $157.00 to $156.00, suggesting a cautious outlook on immediate valuation.
Gilead Sciences (NASDAQ: GILD) saw its stock price surge following FDA approval for Trodelvy in hormone receptor positive/HER2-negative metastatic breast cancer, marking the drug's third indication and a significant milestone as the first Trop-2 targeting ADC to show overall survival benefit in this specific patient group. CEO Daniel O'Day highlighted the transformative role of Trodelvy, noting that oncology sales surged 37% year-over-year in 2023, reflecting strong traction for the company's strategic shift toward cancer therapies alongside its robust HIV business.
The article details Gilead's solid financial position, characterized by a well-covered dividend policy and manageable debt levels. In 2023, the company paid $3.8 billion in dividends and $1.0 billion in share repurchases, supported by $8.0 billion in operating cash flow. With a dividend yield topping 4% and a payout ratio of roughly 68% of net income, Gilead balances shareholder returns with ongoing R&D investments. The balance sheet remains resilient with $8.4 billion in cash equivalents and a net debt-to-EBITDA ratio near 2x, providing ample liquidity for strategic initiatives.
Despite positive momentum, the analysis highlights key risks including heavy reliance on the HIV franchise, which contributed 67% of total revenues in 2023 but faces patent cliffs and pricing pressures. Competition from rivals like AstraZeneca's Enhertu poses a threat to Trodelvy's market share, while recent trial failures in non-small cell lung cancer cast doubt on broader oncology expansion. Analysts view the stock as reasonably valued at mid-teens earnings multiples, offering potential upside if Gilead can successfully execute its growth strategy and validate its pipeline beyond current indications.
📈 FDA approval boosts Trodelvy to third indication with first overall survival benefit.
💰 Oncology sales jumped 37% in 2023 driven by Trodelvy and HIV franchises.
💵 Company returned $4.8 billion via dividends and buybacks supported by $8B cash flow.
⚠️ HIV revenue concentration risks future growth as key drugs face patent cliffs.
🥊 Competition from Enhertu caps Trodelvy peak sales at estimated $600 million.
📈 Gilead's stock surged after FDA approval for Trodelvy in HR+/HER2- metastatic breast cancer, marking the drug's third indication and first overall survival benefit in this category.
💰 Oncology sales grew 37% year-over-year in 2023, driven by strong uptake of Trodelvy and robust performance from the HIV franchise.
📊 The company paid $3.8 billion in dividends and $1.0 billion in share repurchases in 2023, supported by $8.0 billion in operating cash flow.
💵 Gilead maintains a dividend yield above 4% with a payout ratio of roughly 68% of net income, indicating a sustainable and shareholder-friendly policy.
🏦 The balance sheet remains solid with $8.4 billion in cash equivalents and manageable leverage, with only $1.75 billion in notes maturing in 2024.
⚠️ HIV treatments contributed $18.2 billion (67% of revenue) in 2023, creating concentration risk as key drugs face patent cliffs by the early 2030s.
🥊 Competition from AstraZeneca's Enhertu limits Trodelvy's potential market share in HR+/HER2- breast cancer, with Cowen estimating peak sales of only $600 million for this indication.
🔬 Trodelvy failed to meet the primary endpoint in a Phase 3 trial for non-small cell lung cancer (EVOKE-01), casting doubt on its prospects beyond approved indications.
📉 The stock trades at approximately 14–15x trailing PE, offering a discount to the broader market and high single-digit free cash flow yield.
🚀 Morningstar rates GILD a 5-star buy, arguing the stock is undervalued with a wide-moat business and strong dividend potential.
Bullish Signals
FDA approved Trodelvy for breast cancer, first Trop-2 ADC with overall survival benefit.
Onco sales surged 37% YoY in 2023, validating strategic pivot to cancer therapies.
Paid $4.0B to shareholders in 2023 via dividends and buybacks.
Holds $8.4B cash with net debt-to-EBITDA near 2x for R&D flexibility.
Interest coverage at 7x pre-tax earnings ensures comfortable obligation meeting.
Morningstar rates GILD a 5-star buy with wide moat and 30% undervaluation.
HIV franchise provides durable cash flow foundation while oncology pipeline ramps.
Risk Factors
67% revenue reliance on HIV franchise facing early 2030s patent cliffs.
Peak sales limited to $600M due to Enhertu competition in breast cancer.
EVOKE-01 trial failure for lung cancer hinders pipeline expansion beyond approved uses.
$21B Immunomedics acquisition risks stock if Trodelvy misses multi-billion dollar targets.
Increased leverage from acquisitions strains balance sheet and may trigger credit downgrades.
Bullish Signals
FDA approval of Trodelvy for HR+/HER2- metastatic breast cancer marks a transformative step, establishing it as the first Trop-2 ADC to show overall survival benefit in this patient group.
Oncology sales surged 37% year-over-year in 2023, demonstrating strong commercial traction and validating Gilead's strategic pivot toward cancer therapies.
The company generated $8.0 billion in operating cash flow in 2023, more than twice the cash outlay for dividends, ensuring robust coverage of shareholder payouts.
Gilead paid a total of $4.0 billion to shareholders in 2023 ($3.8B dividends + $1.0B buybacks), reflecting strong capital return discipline and confidence in cash generation.
The balance sheet is resilient with $8.4 billion in cash equivalents and a net debt-to-EBITDA ratio near 2x, providing ample liquidity for R&D and acquisitions.
Interest coverage is very healthy at roughly 7x pre-tax earnings, indicating the company can comfortably meet its financial obligations despite moderate leverage.
Morningstar rates GILD a 5-star buy with a wide-moat business, citing a 30% undervaluation and a rich 4% dividend yield compared to peers yielding 2–3%.
The HIV franchise remains a durable cash cow with steady growth, providing a stable foundation for earnings while the oncology pipeline ramps up.
Risk Factors
Heavy reliance on the HIV franchise poses a significant risk, as it contributed 67% of total revenues in 2023 and faces patent cliffs by the early 2030s.
Competition from AstraZeneca's Enhertu limits Trodelvy's potential market share in HR+/HER2- breast cancer, with analysts estimating peak sales of only $600 million for this indication.
Trodelvy failed to meet the primary endpoint in a Phase 3 trial for non-small cell lung cancer (EVOKE-01), raising concerns about its ability to expand beyond approved indications.
The $21 billion Immunomedics acquisition carries high expectations; if Trodelvy fails to reach multi-billion dollar peak sales, it could pressure Gilead's stock and financial returns.
Recent trial failures in oncology R&D, including the EVOKE-01 miss, cast doubt on the company's ability to successfully diversify its pipeline beyond current successes.
Gilead's acquisitive strategy has increased leverage relative to its pre-2020 position, and further large acquisitions could strain the balance sheet or trigger credit rating downgrades.
Cantor Fitzgerald has reiterated an Overweight rating on Gilead Sciences (GILD) with a $155 price target, citing positive Phase 3 clinical trial results for the HIV medication islatravir/lenacapavir. The studies, known as ISLEND-1 and ISLEND-2, demonstrated solid top-line efficacy when administered weekly in collaboration with Merck.
Conversely, Gilead reported negative findings from the EVOKE-03 study, which compared Trodelvy combined with Keytruda against Keytruda monotherapy for first-line PD-L1 non-small cell lung cancer. This mixed clinical data presents a nuanced picture of the company's pipeline performance across different therapeutic areas.
RBC Capital maintained its Sector Perform rating on Gilead Sciences at $122, highlighting the firm's progress in developing in vivo CAR-T technology. Analysts note that this emerging field represents a potential risk to a sector estimated to account for 10-15% of Gilead's potential revenue, though the company is building differentiating features.
The article concludes with promotional content from Insider Monkey suggesting investors look elsewhere for AI stocks, while listing unrelated market movers like Sandisk and BlackBerry. The core financial news focuses on Gilead's specific clinical outcomes and analyst price targets.
📈 Cantor Fitzgerald raised Gilead target to $155 after positive HIV trial results.
💊 Phase 3 studies showed solid top-line results for weekly islatravir/lenacapavir HIV medication.
⚠️ EVOKE-03 study reported negative findings for Trodelvy plus Keytruda in lung cancer.
🔬 RBC Capital reaffirmed rating citing progress in in vivo CAR-T treatment technology.
📊 Gilead develops treatments for HIV, hepatitis, cholangitis, and serious fungal infections.
📈 Cantor Fitzgerald restated an Overweight rating on Gilead Sciences (GILD) with a $155 price target following positive HIV trial results.
💊 Phase 3 studies ISLEND-1 and ISLEND-2 showed solid top-line results for weekly islatravir/lenacapavir for HIV medication in collaboration with Merck.
⚠️ Gilead reported negative findings from the EVOKE-03 study comparing Trodelvy plus Keytruda versus Keytruda monotherapy in non-small cell lung cancer patients.
🔬 RBC Capital reaffirmed a $122 Sector Perform rating, noting Gilead's progress in in vivo CAR-T treatment technology.
⚖️ Analysts identify in vivo CAR-T as a potential risk to a sector representing 10-15% of Gilead's potential revenue.
📊 Gilead develops treatments for HIV-1, hepatitis B/C, primary biliary cholangitis, and serious invasive fungal infections.
🚀 The company also offers T-cell and CAR T-cell therapies for adult patients alongside COVID-19 treatments.
📰 The article includes promotional links to unrelated stock movers like Sandisk (SNDK) and BlackBerry (BB).
Bullish Signals
Cantor Fitzgerald Overweight rating with $155 price target.
Phase 3 success for islatravir/lenacapavir in HIV.
Risk Factors
EVOKE-03 study setbacks hinder Trodelvy plus Keytruda for lung cancer.
CAR-T tech risks threaten 10-15% of Gilead's potential revenue.
Bullish Signals
Cantor Fitzgerald maintains an Overweight rating on Gilead Sciences with a $155 price target, signaling continued institutional confidence.
Positive Phase 3 clinical trial results for islatravir/lenacapavir in HIV treatment demonstrate strong pipeline efficacy and potential commercial value.
Risk Factors
Negative findings from the EVOKE-03 study regarding Trodelvy plus Keytruda in non-small cell lung cancer present a setback for that specific therapeutic combination.
RBC Capital identifies in vivo CAR-T technology as a potential risk to a sector estimated at 10-15% of Gilead's potential revenue.
Gilead Sciences (GILD) is presented as a compelling long-term value opportunity following a recent stock pullback, with the author reaffirming a 'Buy' rating. The article highlights that the company's core HIV franchise remains robust, driving 72% of total sales, primarily through the blockbuster drug Biktarvy and the rapidly adopting Yeztugo.
Management has officially raised its revenue growth guidance for 2026 to a midpoint of 5.5%, citing strong performance in its HIV portfolio alongside growing momentum in oncology with the Trodelvy franchise. This strategic shift underscores confidence in both established cash flows and emerging therapeutic areas.
Financially, Gilead maintains a strong A- rated balance sheet characterized by low leverage and a well-covered 2.65% dividend yield. These fundamentals provide significant strategic flexibility for future investments or shareholder returns, positioning the company to capitalize on its growth runway despite broader market fluctuations.
📈 Gilead offers long-term value after recent stock pullback.
🔬 HIV franchise drives 72% of total sales.
💰 Yeztugo expected to reach $1 billion annual sales.
📊 Management raised 2026 revenue growth guidance to 5.5%.
Gilead Sciences (GILD) recently saw a mix of insider and congressional trading activity. While the company's CEO, Chairman, CFO, and other executives sold a total of approximately $54 million in shares over the last six months with no purchases, several members of Congress made small purchases totaling around $45,000. This divergence has sparked social media discussion regarding potential signals for the biotech sector.
Financially, Gilead reported Q1 2026 revenues of $7 billion, representing a 4.39% increase year-over-year. Institutional investor sentiment remains mixed, with major firms like FMR LLC adding nearly $872 million to their positions while BlackRock and Barclays reduced holdings by over $576 million and $528 million respectively in Q1 2026.
Wall Street analysts maintain a generally positive outlook on the stock. Needham issued a 'Buy' rating, and twelve analysts have set price targets ranging from $122 to $180, with a median target of $165. The company is also advancing its pipeline through recent licensing deals for STAT6 inhibitor programs aimed at oral therapies for inflammation, with data readouts expected in mid-2027.
📉 Insiders sold $54M in shares with zero purchases recently.
👔 Three Congress members bought $45k of GILD stock.
💰 Q1 2026 revenue hit $7B, up 4.39% year-over-year.
🏦 FMR added $871.5M while BlackRock and Barclays cut $1.1B.
📈 Needham rates GILD 'Buy' with median target of $165.
📉 Gilead insiders sold approximately $54 million in shares over the last six months with zero purchases recorded.
👔 Three members of Congress purchased roughly $45,000 worth of GILD stock recently, contrasting with executive sales.
💰 Q1 2026 revenue reached $7 billion, marking a 4.39% increase compared to the same period last year.
🏦 FMR LLC added $871.5 million in shares, while BlackRock and Barclays collectively reduced positions by over $1.1 billion.
📈 Needham issued a 'Buy' rating on GILD, contributing to a positive analyst sentiment environment.
🎯 Analyst price targets for the stock range from $122 to $180, with a median target set at $165.
💊 The company is advancing its pipeline via licensing deals for STAT6 inhibitor programs targeting inflammation.
📅 Data readouts for new oral therapies are anticipated around mid-2027 as part of competitive positioning.
Bullish Signals
Q1 2026 revenues hit $7 billion, up 4.39% year-over-year.
FMR LLC added 6.3 million shares worth $871.5 million.
Analysts set price targets between $122 and $180.
Company expands pipeline with STAT6 inhibitor licensing deals.
Risk Factors
Insiders sold $54M with no purchases.
Institutions cut $1.1B in Q1 2026.
Analysts target $122-$155 vs $180 high.
Bullish Signals
Gilead Sciences reported Q1 2026 revenues of $7 billion, a solid 4.39% year-over-year increase.
Major institutional investor FMR LLC added 6.3 million shares worth approximately $871.5 million to its portfolio in Q1 2026.
Wall Street analysts show bullish sentiment with Needham issuing a 'Buy' rating and twelve analysts setting price targets between $122 and $180.
The company is strategically expanding its pipeline through licensing deals for STAT6 inhibitor programs to advance oral therapies in the inflammation space.
Risk Factors
Gilead insiders, including the CEO and CFO, executed significant sales totaling approximately $54 million over the last six months with no corresponding purchases.
Major institutional holders like BlackRock and Barclays reduced their positions by over $1.1 billion combined in Q1 2026, indicating some profit-taking or rotation.
Several analysts set price targets below current market expectations, such as RBC Capital at $122 and Citigroup at $155, suggesting potential downside risk relative to higher targets like Jefferies' $180.
Gilead Sciences (GILD) recently saw a mix of insider trading activity, with company executives selling shares while members of Congress made purchases. CEO Daniel Patrick O'Day sold 296,280 shares for approximately $41.7 million over the last six months, whereas Representative Jared Moskowitz purchased up to $30,000 in May. This divergence highlights contrasting perspectives on the stock's near-term outlook between management and external investors.
Institutional investor sentiment remains mixed but shows significant capital rotation. Major asset managers like FMR LLC increased their holdings by 9.6% (adding roughly $871 million), while BlackRock, Barclays, and Bank of America reduced positions significantly, with Barclays cutting its stake by over 42%. Despite these large outflows from some giants, the net institutional activity reflects a complex rebalancing rather than a uniform sell-off.
Analyst consensus remains cautiously positive with a median price target of $165. Needham recently issued a 'Buy' rating, and targets range from $122 to $180 across major firms like Citigroup and Morgan Stanley. Financially, Gilead reported Q1 2026 revenues of $7 billion, representing a 4.39% year-over-year increase, indicating stable top-line growth despite the volatility in ownership structures.
The company is also advancing its pipeline with new licensing deals for STAT6 inhibitor programs aimed at oral therapies for inflammation. These strategic moves position Gilead against peers like Johnson & Johnson, with data readouts expected around mid-2027. While insider selling and institutional reductions present some cautionary signals, the revenue growth and analyst support suggest a balanced market view.
📊 Q1 2026 revenue reached $7 billion, up 4.39%.
📉 CEO sold 296k shares for $41.7 million recently.
🏦 FMR added $871M while BlackRock and Barclays reduced stakes.
💊 STAT6 inhibitor data expected in mid-2027.
🎯 Analyst price targets range from $122 to $180.
📊 Gilead Sciences reported Q1 2026 revenues of $7 billion, marking a 4.39% increase from the prior year.
📉 CEO Daniel Patrick O'Day sold 296,280 shares for an estimated $41.7 million in the last six months with zero purchases.
📈 Representative Jared Moskowitz purchased up to $30,000 of GILD stock on May 6, coinciding with other congressional buys.
🏦 FMR LLC added 6.3 million shares (+9.6%) worth ~$871 million in Q1 2026, while BlackRock removed 4.2 million shares (-3.4%).
📉 Barclays PLC reduced its Gilead position by 42.1% (approx. $528 million) and Bank of America cut holdings by 13.6%.
🎯 Wall Street analysts maintain a median price target of $165, with Needham issuing a 'Buy' rating on February 11, 2026.
💊 Gilead is advancing STAT6 inhibitor programs for oral inflammation therapies, with data readouts anticipated in mid-2027.
📅 Analyst price targets range widely from $122 (RBC Capital) to $180 (Jefferies), reflecting varied valuation expectations.
Bullish Signals
Q1 2026 revenue up 4.39% to $7 billion.
FMR LLC added $871 million, increasing position 9.6%.
Needham 'Buy' rating with median target of $165.
Advancing pipeline with new STAT6 inhibitor licensing deals.
Risk Factors
BlackRock sold 3.4% while Barclays cut 42.1%.
Insiders sold over $44 million recently.
Bank of America and Wellington reduced stakes.
Bullish Signals
Gilead Sciences achieved a 4.39% year-over-year revenue increase in Q1 2026, reaching $7 billion.
Major institutional investor FMR LLC increased its GILD position by 9.6%, adding approximately $871 million to its portfolio.
Needham issued a 'Buy' rating on Gilead Sciences, contributing to a positive analyst consensus with a median target of $165.
The company is successfully advancing its pipeline with new licensing deals for STAT6 inhibitor programs in inflammation research.
Risk Factors
Significant institutional selling pressure was observed, with BlackRock reducing holdings by 3.4% and Barclays cutting its position by 42.1%.
Company insiders, including CEO Daniel Patrick O'Day and CFO Andrew D Dickinson, executed only sales totaling over $44 million in the last six months.
Multiple large institutional investors, including Bank of America and Wellington Management, reduced their Gilead positions significantly in Q1 2026.
Gilead Sciences (GILD) is receiving positive attention following the FDA's acceptance of a supplemental filing for Yeztugo, a once-weekly oral tablet for HIV prevention. Concurrently, the company reported positive Phase 3 data for a separate once-weekly HIV treatment regimen, reinforcing its pipeline strength in long-acting therapies.
At a current share price of $123.76, Gilead has experienced short-term declines with a 30-day return of -7.89% and a 90-day return of -10.39%. However, longer-term momentum remains intact, evidenced by a 1-year total shareholder return of 19.58% and a 5-year return of 119.41%. Analysts suggest the stock may be undervalued with a fair value estimate of $128.38.
The company is strategically transitioning from a single-franchise HIV business into a multi-platform biopharma with significant growth drivers in oncology and long-acting HIV prevention. While near-term earnings face headwinds from acquisition spending, the firm possesses one of the deepest pipelines in large-cap biotech, positioning it for a catalyst-rich period where new launches could reshape its earnings mix.
Valuation metrics present a mixed picture; Gilead trades at a P/E ratio of 16.7x, which is slightly above the US biotech average of 16.5x but below a calculated fair ratio of 31x. This discrepancy suggests potential upside if the market re-rates the stock to reflect its broader portfolio and growth prospects, though risks from acquisition-related earnings hits and regulatory setbacks remain.
📈 FDA accepted Yeztugo supplemental filing for once-weekly HIV prevention.
✅ Positive Phase 3 data released for separate once-weekly HIV treatment.
💰 Stock at $123.76 with fair value estimate of $128.38.
🚀 Transitioning from single-franchise model to multi-platform biopharma.
⚠️ Near-term earnings face headwinds due to significant acquisition spending.
📈 FDA accepted supplemental filing for Yeztugo, a once-weekly oral tablet for HIV prevention.
✅ Positive Phase 3 data released for a separate once-weekly HIV treatment regimen.
💰 Current share price is $123.76 with a fair value estimate of $128.38 suggesting potential undervaluation.
📉 Short-term stock performance shows declines: -7.89% over 30 days and -10.39% over 90 days.
📈 Long-term momentum remains strong with a 1-year total shareholder return of 19.58%.
🚀 Company transitioning from single-franchise HIV model to multi-platform biopharma.
💊 Deep pipeline includes high-probability growth drivers in oncology and long-acting HIV prevention.
⚠️ Near-term earnings face headwinds due to significant acquisition spending.
📊 Stock trades at 16.7x P/E, slightly above the US biotech average of 16.5x.
🎯 Analysts note a large gap between current price and intrinsic estimates for some programs.
Bullish Signals
FDA acceptance of Yeztugo filing validates core HIV areas.
Strong 1-year returns of 19.58% show sustained investor confidence.
Pivot to multi-platform model offers diversified oncology and HIV growth.
Valuation gap between $123.76 price and $128.38 fair value.
Resources Management Corp CT ADV significantly reduced its stake in Gilead Sciences (GILD) by 48.6% in the fourth quarter, selling 19,260 shares and ending with a holding valued at approximately $2.5 million. This move contrasts with increased positions from major institutional investors like Vanguard Group, State Street Corp, and Norges Bank, which collectively raised their stakes during the same period.
Gilead reported better-than-expected quarterly financial results with earnings per share (EPS) of $2.03 against a consensus estimate of $1.91, driven by revenue of $6.96 billion that exceeded expectations. The company also declared a quarterly dividend of $0.82 per share, payable on June 29th to shareholders of record on June 15th, offering a yield of roughly 2.6%.
Recent insider activity includes sales by CFO Andrew D. Dickinson and CEO Daniel Patrick O'Day, totaling over $8 million in the last 90 days, though these were executed under pre-arranged Rule 10b5-1 trading plans. Analyst sentiment remains mixed but generally positive, with an average target price of $156.93 and a 'Moderate Buy' rating, while Wall Street firms like Maxim Group have upgraded the stock following positive Phase 3 results for their HIV regimen.
The article highlights Gilead's strong balance sheet with a current ratio of 1.97 and a market cap of $155.93 billion. Key catalysts include advancing clinical trials for oncology prospects like denikitug in colorectal cancer and positive topline results for HIV therapies, alongside neutral-to-negative technical indicators as the stock pulls back from its moving averages.
📉 Resources Management Corp lowered Gilead stake by 48.6% to $2.5M position.
📈 Gilead beat earnings with $2.03 EPS and $6.96B revenue.
💰 Quarterly dividend of $0.82 yields 2.6% for record holders June 15.
👔 Insiders sold $8.18M shares under pre-arranged plans over last 90 days.
🏦 Vanguard and State Street increased Gilead holdings in Q4.
📉 Resources Management Corp CT ADV lowered its Gilead stake by 48.6% in Q4, selling 19,260 shares to end with a $2.5 million position.
📈 Gilead beat quarterly earnings expectations with EPS of $2.03 and revenue of $6.96 billion, surpassing analyst forecasts.
💰 The company declared a quarterly dividend of $0.82 per share, yielding approximately 2.6% for shareholders of record on June 15th.
👔 Insiders including CFO Andrew D. Dickinson and CEO Daniel Patrick O'Day sold shares totaling $8.18 million over the last 90 days under pre-arranged plans.
🏦 Major institutional investors like Vanguard Group and State Street Corp increased their holdings in Gilead during the fourth quarter.
🔬 Positive catalysts include Phase 3 success for an oral HIV regimen and advancement of a Phase 2 study for denikitug in colorectal cancer.
📊 Analyst consensus rates Gilead as a 'Moderate Buy' with an average price target of $156.93, though some firms like Wall Street Zen downgraded the rating.
📉 Technical indicators show short-term pressure as the stock has pulled back from its 50-day and 200-day moving averages.
💵 Gilead maintains a strong financial profile with a market cap of $155.93 billion, a PE ratio of 17.11, and a debt-to-equity ratio of 0.89.
Bullish Signals
EPS of $2.03 beat consensus by $0.12.
Revenue hit $6.96 billion, up 4.4% YoY.
Maxim Group upgraded to buy with $165 target.
Vanguard stake rose 1.8% to 121 million shares.
Quarterly dividend of $0.82 offers 2.6% yield.
Risk Factors
Insiders sold 62,000 shares worth $8.18 million recently.
Stock pulled back from 50-day and 200-day moving averages.
Wall Street Zen downgraded stock to 'hold' in late May.
Erste Group lowered FY2026 earnings estimate slightly.
Bullish Signals
Gilead reported EPS of $2.03, beating the consensus estimate of $1.91 by $0.12.
Revenue reached $6.96 billion, exceeding analyst expectations of $6.91 billion and growing 4.4% year-over-year.
Maxim Group upgraded Gilead from a 'hold' to a 'buy' rating with a $165.00 price target following positive Phase 3 HIV results.
Vanguard Group increased its stake by 1.8%, now holding over 121 million shares worth nearly $14.9 billion.
The company announced a quarterly dividend of $0.82 per share, providing a 2.6% yield to investors.
Gilead is advancing a Phase 2 study for denikitug in difficult-to-treat colorectal cancer, expanding oncology prospects.
Analysts forecast Gilead will post -$0.79 EPS for the current year, though this reflects broader sector loss expectations rather than company-specific weakness.
Risk Factors
Insiders including the CFO and CEO sold a combined total of 62,000 shares worth $8.18 million in the last 90 days.
The stock has pulled back from its 50-day and 200-day moving averages, indicating short-term technical weakness.
Wall Street Zen downgraded Gilead from a 'strong-buy' to a 'hold' rating in late May.
Erste Group slightly lowered its FY2026 earnings estimate, aligning with broader market loss expectations for the sector.
Morgan Stanley Smith Barney LLC has filed a Rule 144 notice regarding the proposed sale of 3,000 shares of Gilead Sciences (GILD) common stock. These specific shares are classified as performance shares originally dated February 4, 2025, and are being registered for resale under standard securities regulations.
The filing also details recent open-market dispositions by individual holder Johanna Mercier. Specifically, the document reports sales of 28,000 shares on May 15, 2026, 3,000 shares on April 15, 2026, and another 3,000 shares on March 16, 2026. Each transaction includes disclosed gross proceeds figures.
This regulatory filing serves as a routine notification to the market about the liquidity of restricted or insider-held securities. It clarifies that these sales are legal under Rule 144 conditions, which govern the resale of locked-up shares after specific holding periods and disclosure requirements are met.
📄 Morgan Stanley filed Rule 144 notice for 3,000 GILD shares on Feb 4, 2025.
💰 Johanna Mercier sold 28,000 shares on May 15, 2026 for $3.67M gross proceeds.
📉 Additional sales included 3,000 shares on April 15, 2026 ($422k) and March 16, 2026.
⚖️ Filings confirm adherence to SEC Rule 144 requirements for reselling restricted securities.
🏢 Morgan Stanley Smith Barney LLC listed as filer representing issuer resale of performance shares.
📄 Morgan Stanley filed a Rule 144 notice for 3,000 GILD common shares classified as performance shares dated February 4, 2025.
💰 Johanna Mercier recently sold 28,000 shares on May 15, 2026, generating gross proceeds of $3,676,197.75.
📉 Additional sales by Johanna Mercier include 3,000 shares on April 15, 2026 ($422,880) and 3,000 shares on March 16, 2026.
⚖️ The filing confirms adherence to SEC Rule 144 requirements for reselling restricted securities to the public market.
🏢 Morgan Stanley Smith Barney LLC is listed as the filer representing the issuer resale of the performance shares.
📅 All reported transactions are categorized as routine open-market dispositions with disclosed consideration amounts.
Bullish Signals
Insider sold 28,000 shares for over $3.6M.
Rule 144 filings show legal selling ability.
No immediate market panic from insider sales.
Risk Factors
Sale of 28,000 shares by Johanna Mercier adds supply.
Executives selling performance shares after meeting targets.
Bullish Signals
The filing confirms that insider Johanna Mercier has successfully converted and sold a significant block of 28,000 shares for over $3.6 million, indicating liquidity in the stock.
Routine Rule 144 filings suggest that insiders are legally able to sell shares without triggering immediate market panic or regulatory scrutiny regarding material non-public information.
Risk Factors
The sale of 28,000 shares by Johanna Mercier adds supply to the open market, which could theoretically exert downward pressure on the share price depending on volume.
Performance shares being sold may indicate that executives have met their specific performance goals and are now liquidating those holdings.
Panagora Asset Management Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.5% in the fourth quarter, selling 321,348 shares and retaining approximately 1.25 million shares valued at $152.9 million. This institutional activity occurred alongside a broader landscape of mixed institutional positioning, where other firms like Empirical Financial Services and Aviva PLC increased their holdings, while Nordea Investment Management AB significantly boosted its position by 16.5%.
Gilead reported strong financial performance for the quarter ended May 7th, posting $2.03 in earnings per share (EPS) against a consensus estimate of $1.91, and generating revenue of $6.96 billion versus an expected $6.91 billion. The company maintained its quarterly dividend at $0.82 per share, offering a 2.6% yield to shareholders, while analysts maintain a constructive outlook with a consensus target price of $156.93 despite the stock trading below recent highs.
Recent developments include positive Phase 3 results for Gilead and Merck's once-weekly oral HIV regimen, which serves as a potential growth catalyst, and the advancement of a Phase 2 study for denikitug in colorectal cancer to expand oncology prospects. However, the stock faces some short-term technical pressure after pulling back from its 50-day and 200-day moving averages, and corporate insiders including CFO Andrew Dickinson sold shares under pre-arranged trading plans.
📉 Panagora cut Gilead stake by 20.5% in Q4.
📈 Gilead beat earnings with $2.03 EPS and $6.96B revenue.
💰 Quarterly dividend of $0.82 offers a 2.6% yield.
🔬 Positive catalysts include successful HIV regimen Phase 3 results.
📊 Analyst consensus is constructive with 25 Buy ratings.
📉 Panagora Asset Management cut its Gilead stake by 20.5% in Q4, selling 321,348 shares while retaining 1.25 million shares worth $152.9 million.
📈 Gilead beat earnings expectations with $2.03 EPS and $6.96 billion revenue, surpassing analyst consensus estimates for both metrics.
💰 The company maintained a quarterly dividend of $0.82 per share, providing a 2.6% yield to investors.
🔬 Positive catalysts include successful Phase 3 results for an HIV regimen and advancement of a colorectal cancer trial.
📊 Analyst consensus remains constructive with 25 Buy ratings and a target price of $156.93, though some targets were recently lowered.
📉 The stock is currently trading below its 50-day and 200-day moving averages, indicating short-term technical weakness.
👔 Corporate insiders sold shares totaling over $8 million in the last three months under Rule 10b5-1 trading plans.
🏦 Institutional ownership stands at 83.67%, with major firms like Nordea and Aviva increasing their positions recently.
Bullish Signals
Beat EPS expectations at $2.03 vs $1.91 consensus.
Revenue reached $6.96B, exceeding estimates of $6.91B.
Offers 2.6% dividend yield with 44.69% payout ratio.
HIV Phase 3 results positive for once-weekly oral regimen.
Consensus target price set at $156.93 with Moderate Buy.
Denikitug Phase 2 study advancing in colorectal cancer.
Risk Factors
Stock pulled back from 50-day and 200-day moving averages.
Panagora Asset Management reduced stake by 20.5% in Q4.
CFO sold over $8 million of shares in three months.
Daiwa Securities lowered price target to $150.
Bullish Signals
Gilead beat earnings expectations significantly, reporting $2.03 EPS compared to the consensus of $1.91.
Revenue of $6.96 billion exceeded analyst estimates of $6.91 billion, demonstrating strong top-line performance.
The company maintains a healthy 2.6% dividend yield with a payout ratio of 44.69%, supporting shareholder returns.
Phase 3 results for the once-weekly oral HIV regimen were positive, acting as a key catalyst for the HIV franchise.
Analyst sentiment remains constructive with a consensus target price of $156.93 and a 'Moderate Buy' rating.
The advancement of the denikitug Phase 2 study in colorectal cancer could broaden the company's oncology pipeline.
Risk Factors
The stock has pulled back from its 50-day and 200-day moving averages, indicating short-term technical pressure.
Panagora Asset Management reduced its stake by 20.5% in Q4, signaling a decrease in confidence from this institutional investor.
Corporate insiders, including the CFO, sold shares totaling over $8 million in the last three months under pre-arranged plans.
Some analysts recently lowered their price targets, with Daiwa Securities reducing its target to $150 and Leerink Partners cutting theirs to $146.
Gilead Sciences and its partner Merck announced positive Phase III data from the ISLEND-1 and ISLEND-2 studies evaluating a once-weekly oral HIV treatment regimen combining islatravir and lenacapavir. Both trials met their primary efficacy endpoint at week 48, demonstrating non-inferior efficacy compared to Biktarvy in ISLEND-1 and standard of care regimens in ISLEND-2, with a safety profile comparable to comparators. Following these results, the companies plan to submit data to regulatory authorities globally, potentially establishing the first long-acting oral HIV treatment with weekly dosing. Gilead's shares gained 2.2% year-to-date against an industry decline of 3.1%, and the company raised its 2026 sales guidance for lenacapavir (Yeztugo) to $1 billion following FDA approval for pre-exposure prophylaxis in early 2025.
Concurrently, Gilead and Merck announced the discontinuation of the Phase III KEYNOTE-D46/EVOKE-03 study evaluating Trodelvy combined with Keytruda as first-line treatment for metastatic non-small cell lung cancer (NSCLC) expressing high PD-L1 levels. The external Data Monitoring Committee recommended stopping the trial after reviewing interim data, noting that while there was a numerical improvement in progression-free survival compared to Keytruda alone, the result lacked statistical significance and the likelihood of achieving a statistically significant overall survival benefit was low. Trodelvy remains approved for metastatic triple-negative breast cancer and HR-positive/HER2-negative breast cancer, with Gilead seeking first-line approval for triple-negative cases. Merck's Keytruda accounts for approximately 50% of its sales, while Gilead continues to expand its HIV franchise amidst competition from long-acting injectables like Cabenuva and Apretude.
🔬 New weekly oral HIV combo met primary efficacy endpoints in Phase III trials.
📈 Gilead raised 2026 lenacapavir sales guidance to $1 billion following positive results.
⚠️ Merck/Gilead discontinued lung cancer study due to lack of statistical significance.
🏥 Trodelvy remains approved for breast cancer with first-line submission pending approval.
🔬 Gilead and Merck announced positive Phase III data from ISLEND-1 and ISLEND-2 studies evaluating an investigational once-weekly oral HIV treatment combining islatravir and lenacapavir.
✅ Both studies met their primary efficacy endpoint at week 48, demonstrating non-inferior efficacy compared to Biktarvy in ISLEND-1 and standard of care regimens in ISLEND-2.
🛡️ The investigational regimen showed a safety profile comparable to comparator treatments with no new safety concerns identified during the trials.
📈 Gilead's shares gained 2.2% year-to-date, contrasting with an industry decline of 3.1%, following the positive HIV study results.
💊 The new combination therapy could become the first long-acting oral HIV treatment with weekly dosing, offering a more convenient option for patients if approved.
📅 Gilead and Merck plan to submit ISLEND trial data to regulatory authorities worldwide and present findings at an upcoming scientific conference.
💰 Gilead raised its 2026 sales guidance for lenacapavir (Yeztugo) to $1 billion, positioning the drug for blockbuster status in its first full year on the market.
🚀 Lenacapavir's approval for HIV prevention has significantly boosted Gilead's HIV franchise due to its twice-yearly dosing compared to daily oral pills.
⚠️ Concurrently, Merck and Gilead announced the discontinuation of the Phase III KEYNOTE-D46/EVOKE-03 study evaluating Trodelvy with Keytruda for metastatic non-small cell lung cancer.
📉 The discontinued NSCLC study showed a numerical but not statistically significant improvement in progression-free survival compared to Keytruda alone.
🏥 Gilead's Trodelvy is currently approved for metastatic triple-negative breast cancer and continues to gain market share in the second-line setting.
🔬 Gilead has submitted supplemental biologics license applications seeking approval of Trodelvy for first-line use in metastatic triple-negative breast cancer patients.
📊 Keytruda alone accounts for around 50% of Merck's sales and is approved for several types of cancer.
🏆 GSK continues to grow its HIV business driven by strong patient demand for long-acting injectable medicines like Cabenuva and Apretude.
📉 Gilead currently holds a Zacks Rank #3 (Hold) according to the article's stock rating system.
Bullish Signals
Gilead/Merck Phase III HIV studies ISLEND-1/2 met primary endpoints at week 48.
Regimen showed non-inferior efficacy vs Biktarvy and standard daily oral therapies.
Could become first weekly-dosing long-acting oral HIV treatment if approved.
Gilead shares gained 2.2% YTD vs industry decline of 3.1%.
FDA approved lenacapavir (Yeztugo) for prevention in 2025 with $1B 2026 sales.
Risk Factors
Gilead/Merck discontinued KEYNOTE-D46/EVOKE-03 due to low OS benefit likelihood.
Trodelvy+Keytruda showed only non-significant PFS improvement vs Keytruda alone.
Gilead faces competition from Cabenuva/Apretude in HIV franchise market.
Bullish Signals
Gilead and Merck announced positive data from two late-stage Phase III HIV studies, ISLEND-1 and ISLEND-2, demonstrating that the investigational once-weekly oral regimen of islatravir/lenacapavir met primary efficacy endpoints at week 48.
In ISLEND-1, the new regimen demonstrated non-inferior efficacy compared to Biktarvy, while in ISLEND-2 it achieved non-inferior results versus standard daily oral antiretroviral therapies.
The investigational combination could become the first long-acting oral HIV treatment with weekly dosing, potentially offering a more convenient option for people living with HIV if approved.
Gilead's shares have gained 2.2% year to date against the industry's decline of 3.1%, reflecting strong market performance following the positive study results.
The FDA approved lenacapavir for prevention under the brand name Yeztugo in 2025, significantly boosting Gilead's HIV franchise with a blockbuster potential of $1 billion in 2026 sales guidance.
Gilead raised its 2026 sales guidance to $1 billion for lenacapavir, positioning the drug to achieve blockbuster status in its first full year on the market.
Trodelvy continues to gain market share in the second-line setting for metastatic triple-negative breast cancer, with Gilead having submitted two supplemental biologics license applications seeking approval for first-line use.
Risk Factors
Gilead and Merck discontinued the Phase III KEYNOTE-D46/EVOKE-03 study evaluating Trodelvy combined with Keytruda for metastatic NSCLC after the external Data Monitoring Committee determined the likelihood of achieving a statistically significant overall survival benefit was low.
The combination therapy showed only a numerical improvement in progression-free survival compared to Keytruda alone, which did not achieve statistical significance, raising concerns about the efficacy of this potential first-line treatment approach.
Gilead faces increasing competition from long-acting injectable HIV medicines like Cabenuva and Apretude from GSK, as well as other competitors in the HIV franchise market.
The article presents a bullish investment thesis for Gilead Sciences, Inc. (GILD), arguing that the market has mischaracterized the company as a slow-growth HIV cash cow while undervaluing its rapidly shifting pipeline. Trading at approximately $133.73 with a forward P/E of 15.22, GILD is positioned for a potential re-rating as investors recognize its transition from traditional HIV treatments to long-acting innovations and credible oncology expansion.
The core value driver identified is the HIV franchise's evolution through lenacapavir, a twice-yearly injectable showing 100% efficacy in trials that could shift adherence economics. Simultaneously, the oncology pillar offers growth via Trodelvy in triple-negative breast cancer and bladder cancer expansion. Despite prior setbacks like magrolimab, these assets provide meaningful optionality currently priced near zero by the market.
Financially, Gilead boasts over $17 billion in operating cash flow and a fortress balance sheet, allowing it to fund long-duration R&D without strain while maintaining a 3.5% dividend yield. The stock trades at a discount to typical pharmaceutical peers and utility-like companies, suggesting the market underestimates the speed of HIV transition and oncology monetization, offering asymmetric upside with limited downside.
While acknowledging near-term revenue headwinds from policy, FX, and COVID normalization noted in previous coverage, the current thesis emphasizes pipeline-driven growth over short-term constraints. The article concludes that GILD offers a compelling setup where successful execution of its innovation portfolio could lead to significant rerating potential given its resilient cash generation base.
📈 Gilead trades at $133.73 with a forward P/E of 15.22.
💉 HIV franchise transitions to lenacapavir with 96-100% trial efficacy.
🔬 Oncology expansion includes Trodelvy in triple-negative breast cancer.
💰 Company holds $17B cash flow for sustained R&D investment.
📉 GILD trades at a discount to peers implying rerating potential.
📈 Gilead Sciences (GILD) is trading at $133.73 with a forward P/E of 15.22, suggesting the market undervalues its multi-platform earnings durability.
💉 The HIV franchise is transitioning to lenacapavir, a twice-yearly injectable with PURPOSE 1 and 2 trials demonstrating 100% and 96% efficacy respectively.
🔬 Oncology expansion includes Trodelvy showing traction in triple-negative breast cancer and additional bladder cancer indications.
💰 The company holds over $17 billion in operating cash flow, supporting sustained R&D investment without financial strain.
📉 GILD trades at a discount to typical pharmaceutical peers and utility-like companies, implying significant rerating potential if execution succeeds.
🛡️ A 3.5% dividend yield anchors downside risk while the fortress balance sheet supports long-duration pipeline development.
🚀 Previous coverage noted revenue headwinds from policy and FX, but current sentiment focuses on pipeline-driven re-rating opportunities.
📊 Hedge fund holdings remained stable at 77 portfolios in Q1, indicating steady institutional interest despite mixed market perception.
Bullish Signals
Lenacapavir trials show 100% efficacy with twice-yearly dosing.
Trodelvy gains traction in triple-negative breast and bladder cancer.
$17B operating cash flow funds R&D without financial strain.
Stock trades at 10-11x forward earnings, a peer discount.
3.5% dividend yield anchors downside risk for investors.
Risk Factors
Lacks top 40 hedge fund popularity status.
Bullish Signals
Gilead's HIV franchise is transitioning to lenacapavir, a twice-yearly injectable with trials showing 100% efficacy, positioning it as a paradigm shift in adherence and prevention economics.
The oncology pipeline offers meaningful optionality with Trodelvy gaining traction in triple-negative breast cancer and expanding into bladder cancer.
Gilead possesses over $17 billion in operating cash flow and a fortress balance sheet, enabling long-duration R&D funding without financial strain.
The stock trades at 10-11x forward earnings, a discount to typical pharmaceutical peers and utility-like companies, implying the market underappreciates its value.
A 3.5% dividend yield provides an income floor that anchors downside risk for investors.
The current valuation suggests the market is not pricing in the successful execution of HIV innovation or oncology monetization trajectories.
Risk Factors
Gilead is not currently on the list of the 40 most popular stocks among hedge funds, indicating some lack of institutional enthusiasm compared to peers.
On June 4, 2026, Gilead Sciences (GILD) and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines to advance their inflammation and immunology pipelines. The deal centers on gamgertamig (OM336), a clinical-stage T cell engager developed as a potential first-in-class treatment for severe autoimmune diseases such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
Under the agreement, Lakefront Biotherapeutics will manage ongoing and future Phase 1/2 clinical studies for gamgertamig, while Gilead Sciences leads registrational and late-stage development. Gilead holds sole global commercialization rights to the asset, with Lakefront entitled to tiered royalties ranging from 20% to 23%. Additionally, Lakefront secured three preclinical autoimmune programs from Ouro, with Gilead retaining an opt-in right for future profit-sharing collaboration.
This strategic move supports Gilead's objective of advancing therapies that transition beyond chronic disease management toward durable immune reset. The acquisition also provides Lakefront with the operational assets and research foundation to accelerate its own development pipeline. Lakefront projects a strong cash balance of approximately €2 billion by the end of 2026 to support further strategic initiatives.
🤝 Gilead and Lakefront acquired Ouro Medicines on June 4, 2026.
💊 Deal centers on gamgertamig (OM336) for severe autoimmune diseases.
🧬 Lakefront secured three additional preclinical autoimmune programs from Ouro.
🤝 Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines on June 4, 2026.
💊 The centerpiece asset is gamgertamig (OM336), a T cell engager targeting severe autoimmune diseases like AIHA and ITP.
📋 Lakefront Biotherapeutics will manage Phase 1/2 clinical studies while Gilead leads registrational and late-stage development.
💰 Gilead holds sole global commercialization rights with Lakefront receiving tiered royalties between 20% and 23%.
🧬 Lakefront secured three additional preclinical autoimmune programs from Ouro Medicines as part of the deal.
🚀 The transaction aims to advance therapies moving beyond chronic management toward durable immune reset.
💵 Lakefront projects a cash balance of approximately €2 billion by the end of 2026 for future initiatives.
Bullish Signals
Gilead acquires Ouro Medicines to bolster inflammation and immunology pipelines.
Deal grants sole global rights for gamgertamig in autoimmune diseases.
Lakefront secures three preclinical programs with future profit-sharing opt-in.
Lakefront projects ~€2 billion cash balance by end of 2026.
Acquisition aligns with Gilead's durable immune reset strategic objective.
Bullish Signals
Gilead Sciences is acquiring Ouro Medicines to significantly bolster its inflammation and immunology pipelines with a first-in-class asset.
The deal grants Gilead sole global commercialization rights for gamgertamig, positioning it as a potential blockbuster in severe autoimmune diseases.
Lakefront Biotherapeutics secures three preclinical programs and maintains an opt-in right for future profit-sharing collaborations with Gilead.
Lakefront projects a robust cash balance of ~€2 billion by the end of 2026, providing ample capital for further strategic initiatives.
The acquisition aligns with Gilead's strategic objective to develop therapies that achieve durable immune reset rather than just chronic disease management.
Gilead Sciences, Inc. and Lakefront Biotherapeutics NV have announced the successful completion of their acquisition of Ouro Medicines for $1.68 billion in upfront equity, with an additional potential of up to $500 million in contingent milestone payments. This transaction adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead's inflammation portfolio and serves as the foundation for Lakefront's development pipeline. The drug is designed to deplete plasma and B cells via subcutaneous administration, aiming for durable disease control in severe antibody-mediated orphan diseases such as autoimmune hemolytic anaemia (AIHA) and immune thrombocytopenia (ITP). It has received Fast Track and Orphan Drug Designation from the US FDA for these indications and is expected to enter registrational studies as early as 2027.
Under the agreement, Gilead acquired all outstanding equity of Ouro Medicines, with Lakefront and Gilead splitting the upfront payment equally and sharing contingent milestones. Lakefront has acquired substantially all of Ouro's team and operational assets and will collaborate on development, responsible for ongoing and future phase 1/2 clinical studies while Gilead leads registrational and later-stage studies. Gilead retains sole worldwide commercialization rights outside Keymed's territories, with Lakefront receiving tiered royalties of 20%–23% on net sales. Additionally, Lakefront has in-licensed a preclinical portfolio of three additional autoimmune programs from Ouro, offering Gilead an opt-in for a 50/50 profit split post clinical proof-of-concept at $75 million per program.
The transaction provides relief under the Option, License and Collaboration Agreement dated July 14, 2019, between Lakefront and Gilead, enabling Lakefront to deploy at least $500 million of its available cash independently, including up to $150 million for share buybacks. Following this deal, Lakefront will continue with a majority of its cash remaining for additional strategic transactions, with an expected year-end 2026 cash balance of approximately €2 billion. The Ouro portfolio is positioned as the cornerstone of Lakefront's R&D pipeline, supporting Gilead's strategy to shift treatment paradigms toward durable immune reset in autoimmune diseases.
🏢 Gilead acquires Ouro Medicines for $1.68B plus milestones to advance T cell engager therapies.
💊 Gamgertamig targets severe autoimmune diseases with FDA Fast Track and Orphan Drug Designation.
🤝 Lakefront retains operational assets, leads early trials, and receives royalties on net sales.
🏢 Gilead Sciences and Lakefront Biotherapeutics have completed the acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.
💊 The deal adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead's inflammation portfolio and serves as the foundation for Lakefront's pipeline.
🎯 Gamgertamig is designed to deplete plasma and B cells via subcutaneous administration with potential for durable disease control in severe antibody-mediated orphan diseases like AIHA and ITP.
⚡ The US FDA has granted Fast Track and Orphan Drug Designation for gamgertamig, with registrational studies expected to begin as early as 2027.
🤝 Gilead acquired all outstanding equity of Ouro Medicines for $1.68 billion plus up to $500 million in contingent milestone payments.
💰 Lakefront and Gilead will split the upfront payment equally, while Lakefront receives tiered royalties of 20%–23% on net sales of gamgertamig from Gilead.
🧬 Lakefront has acquired substantially all of Ouro Medicines' team and operational assets to collaborate with Gilead on developing gamgertamig.
📋 Under the collaboration, Lakefront will lead ongoing and future phase 1/2 clinical studies while Gilead leads registrational and later-stage studies.
🌍 Gilead retains sole worldwide commercialization rights for gamgertamig globally outside of Keymed's territories.
🔬 Lakefront has in-licensed a preclinical portfolio of three additional autoimmune programs from Ouro with an opt-in for Gilead for a 50/50 profit split post clinical proof-of-concept.
💵 The transaction provides relief under the existing Option, License and Collaboration Agreement (OLCA) between Lakefront and Gilead.
📉 This agreement enables Lakefront to deploy at least $500 million of its available cash independently from Gilead, including up to $150 million for share buybacks.
💸 Following the transaction, Lakefront expects to have a majority of its cash remaining for additional strategic transactions and capital allocation priorities.
📊 Lakefront's year-end 2026 cash balance is expected to be approximately €2 billion.
🧬 The Ouro portfolio will serve as the cornerstone of Lakefront's R&D pipeline following this transaction.
Bullish Signals
Gilead acquires Ouro Medicines for $1.68B plus up to $500M milestones.
OM336 holds FDA Fast Track and Orphan Drug Designations for rare diseases.
Gamgertamig targets registrational studies by 2027 for severe antibody-mediated orphan diseases.
Lakefront earns 20%–23% tiered royalties on gamgertamig net sales from Gilead.
Lakefront gains $500M cash relief, enabling buybacks and strategic transactions.
Lakefront expects €2B year-end 2026 cash for additional liquidity.
Risk Factors
Gilead paid $1.68B upfront plus $500M milestones.
Significant capital outlay impacts liquidity or leverage.
Bullish Signals
Gilead Sciences completed the acquisition of Ouro Medicines for $1.68 billion plus up to $500 million in contingent milestone payments, significantly expanding its inflammation portfolio.
The acquired asset gamgertamig (OM336) has received both Fast Track and Orphan Drug Designation from the US FDA for treating autoimmune hemolytic anaemia and immune thrombocytopenia.
Gamgertamig is expected to enter registrational studies as early as 2027, positioning it for potential commercialization in severe antibody-mediated orphan diseases.
Lakefront Biotherapeutics will receive tiered royalties of 20%–23% on net sales of gamgertamig from Gilead, creating a strong revenue stream for the partner.
The transaction provides Lakefront with relief under its existing agreement, enabling it to deploy at least $500 million of available cash independently, including up to $150 million for share buybacks.
Lakefront's year-end 2026 cash balance is expected to be approximately €2 billion, providing substantial liquidity for additional strategic transactions and capital allocation priorities.
Risk Factors
Gilead Sciences paid $1.68 billion in upfront equity plus up to $500 million in contingent milestones for Ouro Medicines, representing a significant capital outlay that could impact liquidity or leverage depending on the company's broader financial context.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)